Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis by P. Invernizzi et al.
Classical HLA-DRB1 and DPB1 Alleles Account for HLA 
Associations with Primary Biliary Cirrhosis
Pietro Invernizzi1,2, Michael Ransom3, Soumya Raychaudhuri4,5,6, Roman Kosoy3, Ana 
Lleo2, Russell Shigeta3, Andre Franke7, Fabrizio Bossa8, Christopher I. Amos9, Peter K. 
Gregersen10, Katherine A. Siminovitch11,12, Daniele Cusi13,14, Paul I.W. de Bakker4,6,15, 
Mauro Podda2, M. Eric Gershwin1, Michael F. Seldin1,3, and and the Italian PBC Genetics 
Study Group16
Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
Corresponding author: Michael F. Seldin, M.D., Ph.D., Biochemistry and Molecular Medicine, University of California, Davis, 
Davis California 95616, USA. mfseldin@ucdavis.edu. 
Disclosures: The authors declare no potential conflicts of interest.
Supplementary Information is available at the Genes and Immunity Web site.
The Italian PBC Genetic Study Group
Piero L. Almasio (Gastroenterology & Hepatology Unit, Di.Bi.M.I.S., University of Palermo, Palermo), Domenico Alvaro 
(Department of Medico-Surgical Sciences and Biotechnologies, Fondazione Eleonora Lorillard Spencer Cenci, University Sapienza of 
Rome, Rome), Pietro Andreone (Dipartimento di Medicina Clinica, Università di Bologna, Bologna), Angelo Andriulli (IRCCS Casa 
Sollievo della Sofferenza Hospital, San Giovanni Rotondo), Cristina Barlassina (Department of Medicine, Surgery, & Dentistry, 
Università degli Studi di Milano, Milan), Antonio Benedetti (Università Politecnica delle Marche, Ancona), Francesca Bernuzzi 
(Center for Autoimmune Liver Diseases, IRCCS Istituto Clinico Humanitas, Rozzano), Ilaria Bianchi (Center for Autoimmune Liver 
Diseases, IRCCS Istituto Clinico Humanitas, Rozzano), MariaConsiglia Bragazzi (Department of Medico-Surgical Sciences and 
Biotechnologies, Fondazione Eleonora Lorillard Spencer Cenci, University Sapienza of Rome, Rome), Maurizia Brunetto (Azienda 
Ospedaliera Universitaria Pisana, Pisa), Savino Bruno (Department of Internal Medicine, Ospedale Fatebene Fratelli e Oftalmico, 
Milan), Lisa Caliari (Center for Autoimmune Liver Diseases, IRCCS Istituto Clinico Humanitas, Rozzano), Giovanni Casella 
(Medical Department, Desio Hospital, Desio), Fabiola Civardi (Center for Autoimmune Liver Diseases, IRCCS Istituto Clinico 
Humanitas, Rozzano IRCCS Istituto Clinico Humanitas, Rozzano), Barbara Coco (Azienda Ospedaliera Universitaria Pisana, Pisa), 
Agostino Colli (Department of Internal Medicine, AO Provincia di Lecco, Lecco), Massimo Colombo (Fondazione IRCCS Ca’ 
Granda, Ospedale Maggiore Policlinico, Milan), Silvia Colombo (Treviglio Hospital, Treviglio), Carmela Cursaro (Dipartimento di 
Medicina Clinica, Università di Bologna, Bologna), Lory Saveria Croce (University of Trieste, & Fondazione Italiana Fegato (FIF), 
Trieste), Andrea Crosignani (San Paolo Hospital Medical School, Università di Milano, Milan), Francesca Donato (Fondazione 
IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan), Luca Fabris (University of Padova, Padova), Carlo Ferrari (Azienda 
Ospedaliero-Universitaria di Parma, Parma), Annarosa Floreani (Dept. of Surgical, Oncological and Gastroenterological Sciences, 
University of Padova, Padova), Andrea Galli (University of Florence, Florence), Ignazio Grattagliano (Italian College of General 
Practicioners, ASL Bari), Roberta Lazzari (Department of Surgical, Oncological and Gastroenterological Sciences University of 
Padova, Padova), Fabio Macaluso (Gastroenterology & Hepatology Unit, Di.Bi.M.I.S., University of Palermo, Palermo), Fabio Marra 
(University of Florence, Florence), Marco Marzioni (Università Politecnica delle Marche, Ancona), Alberto Mattalia (Santa Croce 
Carle Hospital, Cuneo), Renzo Montanari (Ospedale di Negrar, Verona), Lorenzo Morini (Magenta Hospital, Magenta), Filomena 
Morisco (University of Naples, Federico II, Naples), Luca Moroni (Center for Autoimmune Liver Diseases, IRCCS Istituto Clinico 
Humanitas, Rozzano), Luigi Muratori (Department of Clinical Medicine, University of Bologna, Bologna), Paolo Muratori 
(Department of Clinical Medicine, University of Bologna, Bologna), Grazia Niro (IRCCS Casa Sollievo della Sofferenza Hospital, 
San Giovanni Rotondo), Antonio Picciotto (University of Genoa, Genoa), Piero Portincasa (Department of Interdisciplinary Medicine, 
University Medical School, Bari), Daniele Prati (Ospedale Alessandro Manzoni, Lecco, Fondazione IRCCS Ca’ Granda, Ospedale 
Maggiore Policlinico, Milan), Cleofe Prisco (Ospedale Niguarda, Milan), Floriano Rosina (Division of Gastroenterology & 
Hepatology, Center for Predictive Medicine, Gradenigo Hospital, Turin), Sonia Rossi (Department of Internal Medicine, Ospedale 
Fatebene Fratelli e Oftalmico, Milan), Carlo Selmi (IRCCS Istituto Clinico Humanitas, Rozzano), Giancarlo Spinzi (Azienda 
Ospedaliera Valduce, Como), Mario Strazzabosco (Yale University, New Haven, Connecticut 06511, USA and University of Milan-
Bicocca, Monza), Sonia Tarallo (Division of Gastroenterology & Hepatology, Center for Predictive Medicine, Gradenigo Hospital, 
Turin), Claudio Tiribelli (University of Trieste, & Fondazione Italiana Fegato (FIF), Trieste), Pierluigi Toniutto (University of Udine, 
Udine), Maria Vinci (Ospedale Niguarda, Milan), Massimo Zuin (San Paolo Hospital Medical School, Università di Milano, Milan).
HHS Public Access
Author manuscript
Genes Immun. Author manuscript; available in PMC 2013 March 01.
Published in final edited form as:
Genes Immun. 2012 September ; 13(6): 461–468. doi:10.1038/gene.2012.17.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
1Division of Rheumatology, Allergy and Clinical Immunology, Department of Medicine, University 
of California, Davis, Davis, CA 2Center for Autoimmune Liver Diseases, Department of Medicine, 
IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy 3Department of Biochemistry and 
Molecular Medicine, University of California, Davis, Davis, CA 4Divisions of Genetics and 
Rheumatology, Department of Medicine, Brigham and Women’s Hospital, Boston, MA 5Partners 
HealthCare Center for Personalized Genetic Medicine, Boston, MA 6Program in Medical and 
Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA 7Institute of Clinical 
Molecular Biology, Christian-Albrechts-University, Kiel, Germany 8Division of Gastroenterology, 
IRCCS-CSS Hospital, San Giovanni Rotondo, Italy 9Department of Epidemiology, University of 
Texas M.D. Anderson Cancer Center, Houston, TX 10The Robert S. Boas Center for Genomics 
and Human Genetics, Feinstein Institute for Medical Research, North Shore LIJ Health System, 
Manhasset, NY, New York, USA 11Mount Sinai Hospital, Samuel Lunenfeld Research Institute 
and Toronto General Research Institute, Toronto, Ontario, Canada 12Departments of Immunology 
and Molecular Genetics, University of Toronto, Toronto, Ontario, Canada 13Department of 
Medicine, Surgery & Dentistry, Università degli Studi di Milano, Milan, Italy 14Genomics and 
Bioinformatics Unit, Fondazione Filarete, Milan, Italy 15Julius Center for Health Sciences and 
Primary Care, and Department of Medical Genetics, University Medical Center Utrecht, Utrecht, 
The Netherlands 16Italian PC Genetics Study Group members are listed at the end of the 
manuscript
Abstract
Susceptibility to primary biliary cirrhosis (PBC) is strongly associated with HLA region 
polymorphisms. To determine if associations can be explained by classical HLA determinants we 
studied Italian 676 cases and 1440 controls with genotyped with dense single nucleotide 
polymorphisms (SNPs) for which classical HLA alleles and amino acids were imputed. Although 
previous genome-wide association studies and our results show stronger SNP associations near 
DQB1, we demonstrate that the HLA signals can be attributed to classical DRB1 and DPB1 genes. 
Strong support for the predominant role of DRB1 is provided by our conditional analyses. We also 
demonstrate an independent association of DPB1. Specific HLA-DRB1 genes (*08, *11 and *14) 
account for most of the DRB1 association signal. Consistent with previous studies, DRB1*08 (p = 
1.59 × 10−11) was the strongest predisposing allele where as DRB1*11 (p = 1.42 × 10−10) was 
protective. Additionally DRB1*14 and the DPB1 association (DPB1*03:01) (p = 9.18 × 10−7) 
were predisposing risk alleles. No signal was observed in the HLA class 1 or class 3 regions. 
These findings better define the association of PBC with HLA and specifically support the role of 
classical HLA-DRB1 and DPB1 genes and alleles in susceptibility to PBC.
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Introduction
The human major histocompatibility complex, HLA, has been implicated in the 
etiopathogenesis of primary biliary cirrhosis (PBC), similar to many other autoimmune 
diseases. Genome-wide association studies (GWAS) of PBC including our own find the 
strongest association with single nucleotide polymorphisms (SNPs) within the HLA 
region1–3. In these studies the peak association signal is between HLA-DQA1 and HLA-
DQB1. Multiple studies of PBC also show association with particular classical HLA alleles 
in PBC (reviewed in Invernizzi4). These studies have variably implicated different DRB1 
alleles in European populations with most studies including all larger cohorts showing 
association of DRB1*085, 6. Our previous studies in an Italian cohort with PBC showed the 
association of DRB1*08 as predisposing, and DRB1*11 and DRB1*13 as protective 
alleles6. A study using a small cohort (32 German PBC cases and 47 controls) suggest that 
DPB1 associations may also be present in Europeans7. However, a comprehensive study of 
HLA region associations has not been performed and like other autoimmune diseases it is 
unclear which determinants are actually causally related to pathogenesis.
To further study HLA associations in PBC, in the current study we used the most recent 
advances in imputation algorithms and sequence information resources including the 1000 
genome database to accurately impute missing SNPs, and importantly HLA classical alleles. 
Specifically, our investigation rests on recent development and resources for imputing HLA 
classical alleles including a reference set of European subjects8. For our study we used an 
inference set of SNP genotypes from both GWAS and a designed chip array, the 
Immunochip9 that contains a set of SNPs that have been used in multiple studies of HLA10. 
We perform a series of conditioning analyses that clarify which HLA genes and alleles 
underlie the major component of the genetic associations of PBC.
Results
Analyses Show Strong Association of Imputed SNPs and HLA Determinants
To further define PBC - HLA region associations we analyzed association using imputed 
genotypes with high probabilities and information scores (see Materials and Methods). 
These studies utilized genotypes from both GWAS and Immunochip arrays that contained 
large numbers of SNPs in the MHC region (Table 1 Supporting Table 1 and see Materials 
and Methods). Strong association was observed with the peak association (p = 9.83 × 
10−17) with rs115721871 at position 32653792 distal to DQB1 (Fig. 1A, Table 2 and 
Supporting Table 2). Although the strongest associations were with non-coding SNPs, 
multiple classical genes in HLA show strong association with PBC (Table 2). For the 
classical HLA genes the strongest association was with DRB*08 (p = 1.59 × 10−11). The 
DQB1*04:02 and DQA1*04:01 in tight LD with DRB*08 (r2 = 0.84 and 0.89, respectively) 
showed nearly equivalent signals (1.38 × 10−10, 1.90 × 10−10, respectively). Very strong 
association was also observed for DRB1*11 (p = 1.42 × 10−10) with a weaker association 
with the DQB1 allele (DQB1*03:01, p = 6.10×10−9) that is in LD (r2 = 0.75) with 
DRB1*11. Less strong associations were observed with DRB1*14, DQB1*05:03 (6.89 × 
10−7 and 6.21 × 10−7, respectively), and DPB1*03:01 (p =9.18 × 10−7). DQB1*05:03 is in 
nearly complete LD with DRB1*14 (r2 = 0.97). DPB1*03:01 is not in LD with any of the 
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DRB1, DQB1 or DQA1 classical alleles or AAs (r2 < 0.01). There was no association (p > 
10−4) observed for classical alleles in HLA A, B, C or DPA1.
As expected from the analysis of classical HLA alleles, PBC also showed strong association 
with specific AAs in these genes. Most of the HLA AA showing association signals 
corresponded to the key residues that distinguish the specific classical alleles which for 
DRB1, included lysine (L) at AA74 in DRB1 (DRB*08), glutamate (E) at AA58 (DRB*11), 
alanine (A) at AA57 (DRB1*14), and histidine (H) at AA60 (DRB1*14). Similar results 
were observed for specific DQB1, and DQA1 AAs that are in strong LD with specific DRB1 
alleles and AAs (Supporting Table 2).
Conditioning Studies Using Classical HLA Genes
To examine whether these associations could be explained for by known coding differences 
in genes we next performed a series of conditional analyses. These studies were done by 
conditioning on a combination of the alleles from an HLA gene (e.g. DRB1) to control for 
the association that might be attributable to each gene, albeit some of the effect may not be 
directly attributed to that gene due to extensive LD across this region. The residual signals 
after controlling for the effect of various combinations of classical alleles and AA residues 
in these HLA genes show that both DRB1 and DQB1 could account for most of the 
association signal (Fig. 1 B-E, Table 2 and Supporting Table 3). In addition, the signal in the 
DPB1 region was only marginally decreased conditioning on DRB1, DQB1 or DQA1. 
Conditioning on DPB1 eliminated the signal in the DPB1 region and showed a modest 
increase in the signal in the across DRB1, DQA1 and DQB1.
To further assess these conditional analyses, we also examined the relative difference of the 
conditioning by different HLA genes by examining beta estimates and their differences. The 
beta estimate is the measure of the increase in log-odds that can be attributed to each copy of 
a given minor allele. The largest effect is from the composite of DRB1 alleles as shown by 
the residual beta estimates (and odds ratios) after conditioning and the mean change in the 
beta estimates (Table 3). This is most evident examining the SNPs with the strongest signals 
from association (original signal < 5 × 10−8). For example, the DRB1 conditioning had a 
much larger mean change in beta estimate (−0.424) compared with DQB1 (−0.236) (p value 
< 10−10, paired T test). Additional conditional analyses using combinations with DQA1 
demonstrated that DQA1 could not substitute for DRB1 or DPB1 in any of the combinations 
tested (data not shown).
Conditioning on Specific HLA alleles
We next examined the effect of conditioning on specific DRB1, DQA1, DQB1 and DPB1 
classical genes and AAs. A clear pattern emerged showing that the association of groups of 
SNPs was specifically controlled by different alleles. These results are highlighted in Table 
4 and in a more complete version Supporting Table 3. Individually, the specific SNPs 
conditioned a part of the association signal largely corresponding to those SNPs in moderate 
or strong LD (r2 > 0.5) with the particular classical specificity or AA. Similar effects were 
observed for specific alleles in one gene in strong LD with another gene. This is particularly 
evident for the DRB1*14 and DQB1*05:03 in which the effects of controlling for either of 
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these alleles was virtually indistinguishable (Supporting Table 3). Other pairs (e.g. 
DRB1*08 and DQB1*04:02) showed small but consistent differences in which the DRB1 
allele diminished more signal than when the DQB1 allele was used in the conditioning 
analyses (Supporting Table 3). Notably the strongest AA association was at position 74 that 
is in the antigen binding pocket of DRB111, 12.
Similar to when we conditioned on genes (“all” alleles at a particular gene), the DPB1 
region SNP signal was only substantially reduced when DPB1*03:01 (Table 4 and 
Supporting Table 3) or when specific DPB1 AA’s were used in conditioning. The strongest 
effects were observed for the lysine at AA position 11 and the methionine at AA position 76 
that are both members of the 16 AA in the putative antigen binding pocket of this gene11.
Thus, the vast majority of the HLA region association signal can be accounted individually 
by conditioning on one of four specific alleles, three in DRB1 (*08, *11, and *14), and one 
in DPB1 (*03:01). Combinations of these specific alleles accounted for most of the 
remaining signal (Supporting Table 3 and Fig. 1F) and are also reflected in the strong 
reduction in beta estimates (Table 3). However, there are signals from several SNPs in the 
DRB1-DQB1 region that are not accounted for by these conditioning studies. None of these 
SNPs with signals p <10−5 after conditioning on DRB*08, *11 and *14, and DPB1*03:01 
were among the stronger associated SNPs prior to conditioning (all with original association 
p values >10−6). In particular, the strongest associated SNP after conditioning (rs9268668, p 
= 1.67 × 10−7), showed no signal prior to conditioning (p = 0.40). Whether these residual or 
new signals are also due to other specific classical HLA genes is not clear, however, 
conditioning on “all” DRB1 and DPB1 alleles ablated all signals with resulting p-values > 
10−5 (Fig. 1F) suggesting that additional sequence differences (e.g. putative regulatory 
SNPs) do not have to be postulated.
Most of the signal observed for specific AAs was also specifically eliminated when 
conditioning on the DRB1 or DPB1 classical alleles. However, there were several 
exceptions in which the association signal was not readily decreased by controlling for 
single classical HLA alleles. These AAs included DRB1-AA47F, DRB1 AA74A, DQB1-
AA26G, and DQB1-AA74S. For these AAs the signal was ablated when conditioning on 
two DRB1 alleles (DRB1*08 and DRB1*11) (Supporting Table 3). Conversely, 
conditioning on these AA could not account for the association of the most of the other 
SNPs that were not ablated by single classical HLA alleles (Supporting Table 3). Therefore, 
it may be less likely that these particular AAs are critical to explaining the association 
patterns we observed. However, we cannot exclude a specific functional role for these AAs 
and it is notable that DRB1-AA47 and DRB1-AA74 are both in the antigen binding pocket 
of DRB111, 12 and that conditioning on DRB1-AA47F did ablate several of the association 
signals that were not controlled by individual DRB1 classical alleles.
Genotypic Associations
We also examined genotypic associations including combinations of susceptibility alleles 
and combinations of risk susceptibility and protective alleles. Examining individuals with 
combinations of risk alleles DRB1*08 combined with DPB1*03:01 or DRB1*14 combined 
with DPB1*03:01 we found higher odds ratios for disease association than when examining 
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only individuals with single susceptibility alleles (Supporting Table 4). There were 
insufficient numbers of DRB1*08/DRB1*14 (frequency <1%) to evaluate these 
heterozygote genotypes. The increased risk of the combining DPB1*03:01 with DRB1*08 
or DRB1*14 was observed whether DPB1*0301 was on the same or different haplotype as 
that of the DRB1 risk allele (Supporting Table 4). When risk alleles were combined with the 
DRB1*11 protective allele the odds ratios were near 1 and there was no significant 
association with disease.
Finally, we also examined the cumulative combination of risk predisposing and protective 
alleles (Table 5 and Supporting Table 4). The count of predisposing alleles minus protective 
alleles showed a strong correspondence with the odds ratio for PBC. Individuals with an 
excess of one or two or more risk alleles showed an odds ratio (OR) of 3.05 and 5.25 
between cases and controls, and conversely individuals with an excess of one or two or more 
protective alleles had OR of 0.5 or 0.38, respectively (Table 5). All results were compatible 
with an additive model of action between each of the alleles similar to our previous 
observations6.
Discussion
The current study of PBC association with HLA differs from previous investigations by 
providing the most comprehensive analysis of the entire HLA region while correcting for 
multiple confounding factors. Our results are consistent with a predominant role for class II 
genes and we believe exclude any substantial effect from either HLA class I or class III 
genes (there were no residual signals for these genes with p <0.0005 after accounting for 
class II genes). This contrasts other autoimmune diseases in which HLA class I or class III 
plays a predominant role (e.g. myasthenia gravis13) or strong class I gene effects are 
observed independent of class II associations (e.g. type 1 diabetes14 and multiple 
sclerosis15, 16).
Our study strongly suggests that the major gene in HLA that underlies susceptibility to PBC 
is DRB1. Overall DRB1 alleles show the strongest associations and conditioning studies 
show that DRB1 could account for almost all (except DPB1 region) of the association 
signal. HLA-DQB1 shows association that is only marginally less than that observed for 
DRB1. However, several points suggest that these associations are secondary to the strong 
LD between DRB1 and DQB1: 1) the overall strength of association of particular DRB1 
alleles is stronger than the corresponding DQB1 allele; 2) conditioning on DRB1 could 
account for all DQB1 associations; and 3) residual beta-estimates after conditioning showed 
a substantially stronger DRB1 than DQB1 effect.
In addition, our study provides strong evidence for an independent effect of DPB1. Although 
previous studies have as indicated in the introduction suggested DPB1 associations in PBC, 
these were based on small subject sets and were difficult to evaluate. Our study 
demonstrates that the association of DPB1 cannot be accounted for by controlling for other 
HLA region genes. These results are also consistent with findings in some, but not other, 
autoimmune diseases in which an independent effect of DPB1 has been reported. These 
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include juvenile idiopathic arthritis17, type 1 diabetes18, multiple sclerosis16, 19 and 
particular autoantibodies in systemic lupus erythematosus20.
We note that our study does not directly address whether DRB3, DRB4, DRB5 or structural 
variations might have additional independent associations. At present such studies are 
challenging due to absence of reference sets for imputation and/or difficulty in assessing 
these polymorphisms including whether missing genotypes (excluded SNPs with call rates 
<0. 95) may have excluded analysis or inclusion of SNPs within these genes in available 
arrays.
This study has also addressed the association of specific HLA-gene alleles. Most of the HLA 
association with PBC can be attributed to specific associations with DRB1*08, DRB1*11, 
DRB1*14 and DPB1*03:01. DRB1*08 has the strongest association, followed by DRB1*11 
consistent with several previous studies6, 7. PBC associations with DRB1*14 has not been 
previously demonstrated, however, this weaker effect is supported by our conditioning 
studies that show that this classical allele can control for a set of associated SNPs and AAs 
that are not strongly influenced by other classical alleles (Table 3 and Supporting Table 3). 
The DPB1*0301 association is consistent with a previous study of a small German cohort7.
In a previous study we observed that DRB1*13 was a protective allele6. In the current study 
the association of DRB1*13 was weak (p = 4.9 × 10−3, OR= 0.69, 95% CL = 0.53 – 0.89) 
compared to the previous study (p = 3.6 × 10−6). This may be due to several factors: i) the 
previous study did not explicitly control for population substructure; ii) the overlap of 
subjects with the previous study is < 25% and the difference may reflect statistical noise; 
and iii) the previous study used DNA typing rather than the imputation used in the current 
study. It may be worth noting that DRB1*13 like DRB1*11 has an alanine at AA position 
74 and thus contributes to the protective effect observed for this AA (p = 1.33 × 10−11, 
Supporting Table 3). Similarly, our previous study6 showed only a marginal association of 
DRB1*14 (uncorrected p value = 0.004) compared with a strong association (p = 6.9 × 10−7) 
observed in our current study. Here, the conditioning study results including the effect of 
controlling SNPs with very strong associations (see group 3, Table 4) provide additional 
support for the role of DRB1*14.
Finally, we have also considered specific HLA AAs. Most of the associated AAs are both 
nearly unique to the specific HLA classical alleles discussed above and also correspond to 
critical residues for the antigen binding pocket. Thus, associated AAs in DRB1 at AA 
positions 37, 47, 57, 60, 67, 70 and 74; and DPB1 at AA positions 9, 11, 76, 84, 87 are 
antigen pocket AAs11, 12. Consistent with our results strong associations have been recently 
observed with serine at position 57 and leucine at position 74 in a Japanese PBC cohort21. 
We also note that many of the associated DQB1 AAs are also in critical residues for antigen 
binding (DQB1-AA13, 26, 70, 71, 74)11, 12. Of the DRB1 associated only AA58 is not 
among the AAs in this functional class, whereas for DQB1 several are not in this functional 
class (DQB1-AA45, 56, 75, 167, 185).
In conclusion, the most parsimonious explanation consistent with the current study is that 
classical HLA genes and the coding variations within these genes are responsible for the 
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HLA associations with PBC. Although we cannot exclude the possibility that other sequence 
variations affecting for example gene regulation could be important, our data indicates that a 
limited set of classical DRB1 and DPB1 alleles are sufficient to explain HLA associations 
with this disease. We believe the current data provides cogent information for understanding 
HLA-associations in PBC. Studies in other ethnic groups both within Europe and in other 
continental groups will also be important in further definition of the role of particular HLA 
genes and alleles. Lastly, our results provide additional rational for functional studies 
examining specific HLA genes and their relative binding to the putative disease associated 
epitopes of the PDC-E2 the immunodominant autoantigen epitopes of PBC22 23.
Materials and Methods
Study Population and design
The Italian PBC cases were obtained through a multi-center study and met internationally 
accepted criteria for the diagnosis of PBC as detailed in a previous study6. Each of the 
included cases also met ancestry criteria as defined below (see Ancestry). Controls were 
derived from several sources and this sample set information is detailed in Supporting Table 
1. After data filtering and ancestry analyses contained 676 Italian PBC cases and 1440 
Italian controls. All subjects enrolled in the study provided written informed consent and the 
study followed ethical guidelines of the most recent revision of the Declaration of Helsinki 
(Edinburgh, 2000).
All samples were genotyped with either Illumina (San Diego, CA 92121) genome-wide 
and/or Immunochip SNP platforms and the participants included the dataset from our 
previous GWAS as well as new samples (see Supporting Table 1). With the exception of 
ancestry information and assessment of relatedness the current study was restricted to 
genotypes in an ~4 megabase segment of human chromosome 6 (bps 28911802 – 33813043, 
HG19 map). This dataset comprised a minimum of 1548 and a maximum of 5489 genotyped 
SNPs in each individual (Supporting Table 1) and was used for the SNP and HLA 
imputations (see Imputation).
Data Filtering
We used stringent quality control criteria to ensure that high-quality data were included in 
the analyses. We excluded individuals who had >5% missing data and all individuals with 
cryptic relatedness and duplicate samples based on identity-by-descent status for genome-
wide SNPs (PI^ > 0.15) using PLINK24.
We included only SNPs with <5% missing data, Hardy-Weinberg (H-W) equilibrium p 
values >10−4 in controls and >10−5 in combined cases and controls (to exclude most 
genotyping errors) applying these procedures in a stepwise approach separately for each 
dataset. For each of the separately derived control genotyping sets (Supporting Table 1), 
SNPs were excluded if they failed the above criteria within the individual control set or in 
combination with any of the other control groups, or in the complete data set. The H-W 
criteria were applied after exclusion of non-European individuals (see Ancestry). Finally, 
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SNPs were excluded if allele frequency differed by > 10% between different control subject 
groups.
Ancestry
European ancestry was determined using 883 genome-wide SNPs with minimal or no 
linkage disequilibrium (LD) (r2 < 0.1). SNPs analyzed using the STRUCTURE v2.1 
program25 and subjects of known European, Amerindian, East Asian and West African 
origin as previously described26. We used STRUCTURE to exclude non-European and 
admixed study participants since this method allows exclusion/inclusion criteria to be set 
using reference populations. Subjects with >15% non-European ancestry were excluded 
from further analysis.
Italian ancestry was defined using principal components analyses (PCA). For subjects with 
GWAS data, we used the same methods and criteria applied in a previous study with largely 
the same dataset. Briefly, PCA was performed using the EIGENSOFT statistical package27 
utilizing 34 thousand SNPs distributed throughout the genome (r2 < 0.1) that we have 
previously used to define population genetic substructure2. These analyses used an 
independent set of Italian subjects for establishing membership [+/− 2 standard deviations 
(sd) in first 4 principal components (PCs)]. In the current study, a substantial portion of the 
samples did not have GWAS data (Supporting Table 1). For these samples we used a set of 
12,579 SNPs from the Immunochip for which our empiric analyses demonstrated the ability 
of this set to discern Italian ancestry and exclude both other European ethnicities including 
Sardinian Italians (Supporting Fig. 1). Using the GWAS defined individuals, the 
Immunochip only genotyped samples were included using 2 sd in the first 4 PCs. In addition 
to the subject selection, we used the eigenvalues from the first four PCs (only the first four 
PCs were significant based on Tracy-Widom statistics) as covariates in our association 
analyses.
Imputation
We imputed SNPs, HLA classical alleles, and HLA gene amino acids (AAs) using phased 
reference genotypes from both the 1000 genome sequencing project (interim release June 
2011) (http://www.1000genomes.org/) and an HLA defined reference set8. For the 1000 
genome imputation we used IMPUTE version 228 under default parameters. The reference 
haplotypes for this imputation were from 1094 subjects including 381 European subjects and 
98 Tuscan Italians. The number of genotyped (inference) SNPs that overlapped with the 
1000 genome reference set ranged from 1435 SNPs (samples typed by GWAS), 4386 
(samples typed by Immunochip) to 4981 SNPs (samples typed by GWAS plus Immunochip) 
(Supporting Table 1). For subsequent data analyses we utilized only imputed genotypes with 
maximum posterior probability scores of > 0.90. Using this parameter our empiric testing 
(leave one-out analyses) indicated that the maximum error rate for genotype assignment was 
< 0.05 and the mean error rate was < 0.01. To impute classical HLA alleles and 
corresponding amino acids determinants we utilized a reference separate dataset of collected 
by the Type 1 Diabetes Genetics Consortium (T1DGC). This reference data contains 
genotype data for 2,537 SNPs, selected to tag the entire MHC, and classical types for HLA-
A, B, C, DRB1, DQA1, DQB1, DPA1 and DPB1 at 4-digit resolution in 2767 unrelated 
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individuals of European descent29. The Beagle software package30 was used for this 
imputation under default parameters. The number of inference SNPs that overlapped with 
this reference dataset ranged from 648 (samples typed by GWAS), 1444 SNPs (samples 
typed by Immunochip) to 1610 SNPs (GWAS plus Immunochip) (Supporting Table 1). 
Similar to the imputation using 1000 Genome data, only SNPs with posterior probabilities of 
>0.90 were included in our final analyses. For imputed SNPs that overlapped between the 
two imputation sets and algorithms used (Impute V2.0 and Beagle) there was a nearly 
complete concordance of the association testing results indicating similar performance of 
these algorithms for this dataset. After imputation and selecting only those markers meeting 
posterior probability criterion this region contained a total of 49,885 markers including the 
genotyped SNPs that were included in association test analyses.
Association and Conditional Association Tests of Imputed SNPs and HLA determinants
SNPTEST V2.028 (web) was used for the primary association analyses for the imputed 
genotypes. This software uses the genotype probabilities for the imputed SNPs or 
determinants and accounts for genotype uncertainty. The first four PC eigenvalue scores 
were used as continuous variables in the association test together with the gender covariate. 
Analyses were performed using the SNPTEST v2 Score test algorithm that enabled both the 
inclusion of the covariates and conditioning tests and all of our reported results used an 
additive model. To minimize potential spurious results we limited our main and conditioning 
analyses to markers with information scores (Inf) > 0.85. This parameter is a measure of the 
observed statistical information for the estimate of SNP allele frequency (for additional 
information see https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.v2.pdf).
Conditioning on multiple markers either separately or together was performed using an 
additive model. For the HLA region, over 150 conditional analyses were performed using 
the SNPs and HLA determinants including all HLA determinants with p values < 10−6.
Nominal p values after correction for covariates and conditioning are provided throughout 
the manuscript. The p-values <10−6 would remain significant after conservative 
(Bonferroni) correction for the number of markers (<50,000) tested after imputation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Analysis of the HLA region association signals in PBC
In each panel, the symbols show the strength of the association signal (ordinate) for the 
corresponding position (Mb, HG19) on chromosome 6 (abscissa). For panel A, the p value 
before conditioning is shown. For panels B-F the p values are shown after conditioning on 
the HLA determinant(s) indicated in the panel. The blue color coded symbols denotes the 
strongest associated marker with p value <10−6, and the other markers are color coded to 
indicate marker LD with the strongest associated marker: Markers with strong LD (r2 > 0.8) 
(red); moderate LD (r2 > 0.5) (orange), weak LD (r2 > 0.2) (yellow) and little or no LD 
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(open symbols) are shown. The SNPs with the strongest associations were rs115721871 at 
bp 32653792 (panels A and D), rs9277558 at bp 33056711 (panels B and C), and rs9268668 
at bp 32413889 (panel F).
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Table 5
Cumulative Effect of Risk and Protective Classical HLA Alleles for PBC Susceptibility
Categorya Controls
Number (%)b
Cases
Number (%)
Odds Ratio p-value
RISK - PROTECTIVE =/< −2 177 (12.3) 34 (5.0) 0.38 5.87E-08
RISK - PROTECTIVE =/< −1 682 (48.1) 185 (27.4) 0.50 2.03E-12
RISK - PROTECTIVE = 0 522 (36.3) 246 (36.4) 1.00 NS
RISK - PROTECTIVE =/> +1 226 (15.7) 245 (36.2) 3.05 6.94E-25
RISK - PRPTECTIVE =/> 2 32 (2.2) 72 (10.7) 5.25 1.37E-15
a
This table shows the results of categorizing each participant based on the sum of the each risk allele (positive number) and each protective allele 
(negative number). The risk alleles are DRB1*08, DRB1*14 and DPB1*03:01. The protective alleles are DRB1*11 and DRB1*13. The alleles 
were determined from the most probable allele after imputation and haplotype analyses (see Methods).
b
The number of subjects that are in each category are shown together with the % of total controls (1440) or percent of cases (676).
c
The two tailed Fisher exact p value from contingency table analyses comparing cases and controls in each category.
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